Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AKCA Akcea Therapeutics (AKCA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Akcea Therapeutics Stock (NASDAQ:AKCA) 30 days 90 days 365 days Advanced Chart Ad DTIEver heard of this 8-day bitcoin profit window? Did you know Bitcoin almost always soars higher during an 8-Day Profit Window? Most people have no clue… But for over a year now, some of our top students have had the chance to cash in with some incredible gains during this 8-day window.It’s coming up quick. Get Akcea Therapeutics alerts:Sign Up Key Stats Today's Range$18.17▼$18.1750-Day Range$18.13▼$18.1752-Week Range$8.00▼$21.70VolumeN/AAverage Volume361,806 shsMarket Capitalization$1.85 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewAkcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.Read More… Ever heard of this 8-day bitcoin profit window? (Ad)Did you know Bitcoin almost always soars higher during an 8-Day Profit Window? Most people have no clue… But for over a year now, some of our top students have had the chance to cash in with some incredible gains during this 8-day window.It’s coming up quick. Receive AKCA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akcea Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address AKCA Stock News HeadlinesArcturus Therapeutics Holdings Inc ARCTJanuary 6, 2024 | morningstar.comAKCA Historical DataSeptember 27, 2023 | investing.com“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as we wait for Trump's agenda to kick in…November 23, 2024 | Colonial Metals (Ad)Akcea Therapeutics Inc (AKCA)January 5, 2022 | investing.comAkcea Therapeutics to Present at Upcoming Investor ConferencesOctober 26, 2021 | finance.yahoo.comSee More Headlines AKCA Stock Analysis - Frequently Asked Questions How were Akcea Therapeutics' earnings last quarter? Akcea Therapeutics, Inc. (NASDAQ:AKCA) announced its quarterly earnings results on Tuesday, August, 4th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by $0.14. The company's revenue was down 15.9% compared to the same quarter last year. When did Akcea Therapeutics IPO? Akcea Therapeutics (AKCA) raised $125 million in an IPO on Friday, July 14th 2017. The company issued 9,600,000 shares at $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities served as the underwriters for the IPO and BMO Capital Markets was co-manager. What other stocks do shareholders of Akcea Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Akcea Therapeutics investors own include Ionis Pharmaceuticals (IONS), Intelsat (I), Bank of America (BAC), Advanced Micro Devices (AMD), Ciena (CIEN), Fossil Group (FOSL) and AMC Entertainment (AMC). Company Calendar Last Earnings8/04/2020Today11/23/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:AKCA CUSIPN/A CIK1662524 Webwww.akceatx.com Phone617-207-0202FaxN/AEmployees248Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.48 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$40.77 million Net Margins-12.34% Pretax MarginN/A Return on Equity-8.94% Return on Assets-8.02% Debt Debt-to-Equity RatioN/A Current Ratio12.17 Quick Ratio11.78 Sales & Book Value Annual Sales$488.54 million Price / Sales3.78 Cash Flow$0.51 per share Price / Cash Flow35.54 Book Value$5.78 per share Price / Book3.14Miscellaneous Outstanding Shares101,599,000Free FloatN/AMarket Cap$1.85 billion OptionableOptionable Beta1.45 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report This page (NASDAQ:AKCA) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akcea Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akcea Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.